---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-124597"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2024-12-02T23:59:59+00:00"
generated_at: "2026-05-29T11:42:13.623983+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TransCode raises ~$8M in private placement; expects to regain Nasdaq compliance

## Summary
- Issued 21.2M shares/pre-funded warrants, 21.2M Series C and 21.2M Series D warrants at $0.377/unit.
- Warrants exercisable at $0.475; Series C 5-year term, Series D 2.5-year term after stockholder approval.
- Gross proceeds ~$8M; proceeds for working capital and general corporate purposes.
- Regained compliance with Nasdaq $2.5M minimum equity requirement after private placement; awaiting final determination.
- Benchmark Company acted as exclusive placement agent; cash fee $50,000.

## SEC filing metadata
- accession: 0001104659-24-124597
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2024-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465924124597/0001104659-24-124597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465924124597/tm2429720d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-124597
- JSON: https://secwatch.observer/filing/0001104659-24-124597.json
- Plain text: https://secwatch.observer/filing/0001104659-24-124597.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.